GNFT vs. GRPH, CGEN, CADL, PSTX, LENZ, VCXB, INMB, IPSC, KOD, and CRDF
Should you be buying Genfit stock or one of its competitors? The main competitors of Genfit include Graphite Bio (GRPH), Compugen (CGEN), Candel Therapeutics (CADL), Poseida Therapeutics (PSTX), LENZ Therapeutics (LENZ), 10X Capital Venture Acquisition Corp. III (VCXB), INmune Bio (INMB), Century Therapeutics (IPSC), Kodiak Sciences (KOD), and Cardiff Oncology (CRDF). These companies are all part of the "biological products, except diagnostic" industry.
Graphite Bio (NASDAQ:GRPH) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, community ranking, profitability, risk, analyst recommendations, dividends and media sentiment.
Genfit received 51 more outperform votes than Graphite Bio when rated by MarketBeat users. Likewise, 67.74% of users gave Genfit an outperform vote while only 37.50% of users gave Graphite Bio an outperform vote.
Genfit has higher revenue and earnings than Graphite Bio.
54.3% of Graphite Bio shares are held by institutional investors. Comparatively, 2.2% of Genfit shares are held by institutional investors. 38.4% of Graphite Bio shares are held by insiders. Comparatively, 4.2% of Genfit shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Graphite Bio's return on equity of 0.00% beat Genfit's return on equity.
Graphite Bio has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Comparatively, Genfit has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.
Genfit has a consensus price target of $11.00, indicating a potential upside of 222.58%. Given Graphite Bio's higher probable upside, analysts clearly believe Genfit is more favorable than Graphite Bio.
In the previous week, Genfit's average media sentiment score of 0.00 equaled Graphite Bio'saverage media sentiment score.
Summary
Genfit beats Graphite Bio on 9 of the 11 factors compared between the two stocks.
Get Genfit News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
